# IDL Diagnostics

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/idldiagnostics).

## Overview

IDL Diagnostics is a Swedish in vitro diagnostics company focused on biomarker-based tests for urology and bacteriology. Its portfolio includes rapid tests, laboratory assays, and products designed for automated platforms, with operations conducted through its subsidiary IDL Biotech and supporting entities in the group.

## Products & services

• UBC®Rapid bladder cancer test
• TK 210 ELISA urology assay
• TUBEX® bacteriology test
• TPS tests for automated platforms
• Biomarker diagnostics for oncology and infection

- **Urology diagnostics** (45%) — Tests used to detect and monitor urological disease, including bladder cancer biomarkers.
- **Bacteriology diagnostics** (25%) — Assays for identifying bacterial infections and supporting clinical decision-making.
- **Automated platform tests** (20%) — Tests designed for use on automated readers and partner platforms in clinical labs.
- **Other biomarker diagnostics** (10%) — Additional biomarker-based products and development-stage diagnostic offerings.

- UBC®Rapid bladder cancer test
- TK 210 ELISA urology assay
- TUBEX® bacteriology test
- TPS tests for automated platforms
- Biomarker diagnostics for oncology and infection

## Customers

IDL Diagnostics sells to healthcare and laboratory customers that need reliable biomarker tests for early detection and follow-up of disease. Its products are used in clinical settings, including hospitals, laboratories, and partner-led diagnostic channels, with emphasis on urology, infection, and oncology applications. The company also works through distributors and platform partners in international markets, where registration and market access are important buying criteria.

- **Hospitals and specialist clinics** (primary) — Buy UBC and related tests for early detection and monitoring of disease in clinical care pathways.
- **Clinical laboratories** (primary) — Use ELISA and bacteriology assays for routine testing and diagnostic workflows.
- **Diagnostic distributors and platform partners** (secondary) — Buy or license products to commercialize them in local markets and on automated readers.
- **Physicians and specialist end users** (secondary) — Influence adoption by selecting tests that improve early diagnosis and follow-up.

- Hospitals and clinical departments using biomarker tests for diagnosis
- Clinical laboratories that run ELISA and automated-platform assays
- Distributors and diagnostic partners in export markets
- Physicians and specialists in urology and bacteriology
- Partner platforms that need compatible tests for their readers

## Geography

IDL Diagnostics is headquartered in Stockholm, Sweden, and its operational activities are run through IDL Biotech. The company serves existing markets in Europe and is actively building presence in new international markets, including China and the Middle East through partners and joint ventures. Geography matters because market access, registrations, and local distribution relationships are central to selling diagnostics outside the home market.

- **Sweden** (35%) — Estimated home-market share based on Swedish headquarters and group operations.
- **Europe** (45%) — Estimated European commercial footprint across established and partner markets.
- **Asia** (15%) — Includes China-focused partner development and registration work.
- **Middle East** (5%) — Reflects business development activity around Dubai and regional outreach.

- Headquartered in Stockholm, Sweden
- Operational activities are conducted through IDL Biotech
- Sales and partner activity extend into Europe and export markets
- China is a priority market for registrations and partner expansion
- Dubai/WHX exposure supports broader Middle East market development

## Strategy

IDL Diagnostics is focused on expanding sales of its existing biomarker tests while securing registrations and market access in new priority countries. The company is also developing automated-platform offerings and partnerships so its products can reach broader clinical workflows and larger addressable markets.

- **International market expansion** (medium-term) — Diagnostics growth depends on local registrations, distribution, and clinical adoption in new countries.
- **Automated platform commercialization** (medium-term) — Platform-compatible tests can scale through installed readers and partner channels.
- **Portfolio development** (long-term) — New biomarkers and improved assays support broader clinical use and future growth.

- Expand sales of existing biomarker tests in current markets
- Obtain registrations in new priority countries
- Grow automated-platform sales through partner readers
- Use joint ventures and distributors to broaden market reach
- Develop next-generation diagnostics for prioritized indications

## Risks

IDL Diagnostics depends on regulatory approvals, clinical adoption, and distributor execution to convert its biomarker portfolio into sales. The business is also exposed to competition from other IVD providers, reimbursement and procurement pressure, and the risk that new products or market entries take longer than expected.

- **Regulatory and registration delays** [high] — New markets require product approvals and studies before commercialization.
- **Partner and distributor dependence** [medium] — A meaningful part of international growth relies on third-party commercialization.
- **Competitive IVD market** [medium] — Alternative diagnostics and larger competitors can limit market share gains.
- **Clinical adoption risk** [medium] — Hospitals and labs may adopt new tests slowly without clear workflow benefits.

- Regulatory approvals can delay launches in new markets
- Sales depend on partner execution and distributor relationships
- Competition in IVD can pressure adoption and pricing
- Clinical uptake may be slower than expected for new biomarkers
- International expansion adds country-specific compliance risk

## Accounting

The company reports under IFRS, so investors should watch how development costs, leases, and intangible assets affect reported results. Revenue can also be influenced by timing of product shipments, partner sales, and market-launch milestones, while impairment testing matters for capitalized development assets and goodwill.

- **IFRS transition** — Equity, profit, and balance sheet presentation may differ from earlier reports
- **Capitalized development and impairment** — Impairment charges could affect earnings and asset values
- **Lease accounting** — Operating expenses and finance costs are split differently under IFRS 16
- **Revenue recognition** — Quarterly revenue may be uneven depending on shipment and acceptance timing

- IFRS reporting affects comparability with prior K3-based periods
- Development costs and intangibles may require impairment testing
- Lease accounting changes operating expense and finance cost presentation
- Revenue timing may vary with partner orders and product shipments
- Cash flow and working capital can move with inventory and receivables

---

*Last updated: 2026-08-11T04:04:53.318986+00:00*